# Michael A Levine

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 245 papers | 11,595 citations | 64 h-index | 98 g-index |
| 250 ext. papers | 12,947 ext. citations | 7.4 avg, IF | 6.21 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 245 | Diagnostic Approach and Treatment of the Pediatric Patient with Hypercalcemia. *Contemporary Endocrinology*, **2022**, 55-73 | 0.3 | |
| 244 | Longitudinal assessment of vascular calcification in generalized arterial calcification of infancy.. *Pediatric Radiology*, **2022**, 1 | 2.8 | |
| 243 | ENPP1 variants in patients with GACI and PXE expand the clinical and genetic heterogeneity of heritable disorders of ectopic calcification.. *PLoS Genetics*, **2022**, 18, e1010192 | 6 | 3 |
| 242 | The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. *BMC Endocrine Disorders*, **2021**, 21, 232 | 3.3 | 0 |
| 241 | An Update on Vitamin D Deficiency in the twenty-first century: nature and nurture. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2021**, 29, | 4 | 4 |
| 240 | A painting of the Christ Child with bowed legs: Rickets in the Renaissance. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2021**, 187, 216-218 | 3.1 | 2 |
| 239 | Mild Idiopathic Infantile Hypercalcemia-Part 2: A Longitudinal Observational Study. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 2938-2948 | 5.6 | 3 |
| 238 | High-throughput Molecular Analysis of Pseudohypoparathyroidism 1b Patients Reveals Novel Genetic and Epigenetic Defects. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e4603-e4620 | 5.6 | 2 |
| 237 | Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 2915-2937 | 5.6 | 1 |
| 236 | Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). *Genetics in Medicine*, **2021**, 23, 396-407 | 8.1 | 14 |
| 235 | Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e485-e495 | 5.6 | 7 |
| 234 | Disorders of Mineral Metabolism II. Abnormalities of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent **2021**, 705-813 | | 2 |
| 233 | Receptor Transduction Pathways Mediating Hormone Action **2021**, 30-85 | | 1 |
| 232 | Vitamin D Metabolism or Action **2021**, 335-372 | | |
| 231 | Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. *Journal of Bone and Mineral Research*, **2021**, 36, 942-955 | 6.3 | 2 |
| 230 | Parenteral iron therapy and phosphorus homeostasis: A review. *American Journal of Hematology*, **2021**, 96, 606-616 | 7.1 | 5 |
| 229 | SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism. *Journal of the Endocrine Society*, **2020**, 4, | 0.4 | 78 |

| | | | |
|---|---|---|---|
| 228 | Diagnosis and Management of Vitamin D Dependent Rickets. *Frontiers in Pediatrics*, **2020**, 8, 315 | 3.4 | 14 |
| 227 | Differential Frequency of CYP2R1 Variants Across Populations Reveals Pathway Selection for Vitamin D Homeostasis. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 3 |
| 226 | Long-acting Growth Hormone Therapy: A REAL3 Alternative to Daily Growth Hormone Treatment?. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 1 |
| 225 | Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism. *European Journal of Endocrinology*, **2020**, 183, K13-K21 | 6.5 | 1 |
| 224 | Hypoparathyroidism in pediatric patients **2020**, 93-106 | | |
| 223 | Hypoparathyroidism in Children **2020**, 79-97 | | |
| 222 | MON-074 Ketotic Hypercalcemia; A Possible Side Effect of Managing Refractory Epilepsy with Ketogenic Diet. *Journal of the Endocrine Society*, **2020**, 4, | 0.4 | 78 |
| 221 | Intragenic Deletions of GNAS in Pseudohypoparathyroidism Type 1A Identify a New Region Affecting Methylation of Exon A/B. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 3 |
| 220 | Vitamin D Therapy and the Era of Precision Medicine. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 1 |
| 219 | Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus. *Pediatric Blood and Cancer*, **2020**, 67, e28036 | 3 | 22 |
| 218 | Single Gland, Ectopic Location: Adenomas are Common Causes of Primary Hyperparathyroidism in Children and Adolescents. *World Journal of Surgery*, **2020**, 44, 1518-1525 | 3.3 | 9 |
| 217 | Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. *Hormone Research in Paediatrics*, **2020**, 93, 182-196 | 3.3 | 16 |
| 216 | Short Stature is Progressive in Patients with Heterozygous NPR2 Mutations. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 8 |
| 215 | Differentiation of PTH-Expressing Cells From Human Pluripotent Stem Cells. *Endocrinology*, **2020**, 161, | 4.8 | 5 |
| 214 | Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 10 |
| 213 | Bones and Joints: The Effects of Cannabinoids on the Skeleton. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 4683-4694 | 5.6 | 9 |
| 212 | Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5136-5147 | 5.6 | 23 |
| 211 | Response to: Obesity and Vitamin D Metabolism Modifications. *Journal of Bone and Mineral Research*, **2019**, 34, 1384 | 6.3 | |

| | | | |
|---|---|---|---|
| 210 | Burosumab treatment of children with X-linked hypophosphataemic rickets. *Lancet, The*, **2019**, 393, 2364-2366 | 42 | 7 |
| 209 | Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. *Journal of Hepatology*, **2019**, 71, 366-370 | 13.4 | 29 |
| 208 | ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. *Nature Medicine*, **2019**, 25, 1116-1122 | 50.5 | 70 |
| 207 | Response to Letter to the Editor: "Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia". *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5100-5101 | 5.6 | 1 |
| 206 | Neonatal severe hyperparathyroidism due to a homozygous mutation of calcium-sensing receptor; a challenging case. *Ceylon Medical Journal*, **2019**, 64, 155-157 | 0.7 | 2 |
| 205 | Pitfalls with Vitamin D Research in Musculoskeletal Disorders and Recommendations on How to Avoid Them. *JCRPE Journal of Clinical Research in Pediatric Endocrinology*, **2019**, 11, 220-226 | 1.9 | 3 |
| 204 | Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. *Journal of Bone and Mineral Research*, **2019**, 34, 1068-1073 | 6.3 | 45 |
| 203 | Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6 Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of GACI. *Journal of Investigative Dermatology*, **2019**, 139, 360-368 | 4.3 | 31 |
| 202 | Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 722-731 | 5.6 | 39 |
| 201 | Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis. *FASEB Journal*, **2018**, 32, 52-62 | 0.9 | 19 |
| 200 | Decreased Serum 25-Hydroxyvitamin D in Aging Male Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance. *Endocrinology*, **2018**, 159, 3083-3089 | 4.8 | 8 |
| 199 | Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. *American Journal of Physiology - Endocrinology and Metabolism*, **2018**, 315, E446-E453 | 6 | 5 |
| 198 | The Role of Genetic Variation in CYP2R1, the Principal Vitamin D 25-Hydroxylase, in Vitamin D Homeostasis **2018**, 303-315 | | 2 |
| 197 | Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. *Human Molecular Genetics*, **2018**, 27, 3233-3245 | 5.6 | 42 |
| 196 | CYP3A4 mutation causes vitamin D-dependent rickets type 3. *Journal of Clinical Investigation*, **2018**, 128, 1913-1918 | 15.9 | 46 |
| 195 | Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum ( ). *Oncotarget*, **2018**, 9, 30721-30730 | 3.3 | 20 |
| 194 | Heterozygous Mutations in TBX1 as a Cause of Isolated Hypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 4023-4032 | 5.6 | 10 |
| 193 | Pseudohypoparathyroidism. *Endocrinology and Metabolism Clinics of North America*, **2018**, 47, 865-888 | 5.5 | 31 |

| | | | |
|---|---|---|---|
| 192 | Genetic Disorders of Parathyroid Development and Function. *Endocrinology and Metabolism Clinics of North America*, **2018**, 47, 809-823 | 5.5 | 20 |
| 191 | Pseudohypoparathyroidism **2018**, 661-673 | | |
| 190 | Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3124-3130 | 5.6 | 9 |
| 189 | Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. *Nature Reviews Endocrinology*, **2018**, 14, 476-500 | 15.2 | 132 |
| 188 | Outcomes of minimally invasive parathyroidectomy in pediatric patients with primary hyperparathyroidism owing to parathyroid adenoma: A single institution experience. *Journal of Pediatric Surgery*, **2017**, 52, 188-191 | 2.6 | 15 |
| 187 | Digenic Inheritance of PROKR2 and WDR11 Mutations in Pituitary Stalk Interruption Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2501-2507 | 5.6 | 23 |
| 186 | Compound heterozygous mutations in COL1A1 associated with an atypical form of type I osteogenesis imperfecta. *American Journal of Medical Genetics, Part A*, **2017**, 173, 1907-1912 | 2.5 | 8 |
| 185 | Exome Sequencing Reveals Mutations in AIRE as a Cause of Isolated Hypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1726-1733 | 5.6 | 28 |
| 184 | Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c. *Bone*, **2017**, 97, 15-19 | 4.7 | 22 |
| 183 | Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3111-3123 | 5.6 | 94 |
| 182 | CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1440-1446 | 5.6 | 47 |
| 181 | CYP2R1 mutations causing vitamin D-deficiency rickets. *Journal of Steroid Biochemistry and Molecular Biology*, **2017**, 173, 333-336 | 5.1 | 36 |
| 180 | Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. *Journal of Bone and Mineral Research*, **2017**, 32, 360-372 | 6.3 | 65 |
| 179 | Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1747-1749.e4 | 11.5 | 17 |
| 178 | The etiology and significance of fractures in infants and young children: a critical multidisciplinary review. *Pediatric Radiology*, **2016**, 46, 591-600 | 2.8 | 41 |
| 177 | Epidemiology and Diagnosis of Hypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 2284-99 | 5.6 | 148 |
| 176 | Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy. *Journal of Investigative Dermatology*, **2016**, 136, 275-283 | 4.3 | 31 |
| 175 | Low bone mineral density is a common finding in patients with homocystinuria. *Molecular Genetics and Metabolism*, **2016**, 117, 351-4 | 3.7 | 17 |

| | | | |
|---|---|---|---|
| 174 | Association of Mutations in SLC12A1 Encoding the NKCC2 Cotransporter With Neonatal Primary Hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 2196-200 | 5.6 | 20 |
| 173 | Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 880-8 | 5.6 | 32 |
| 172 | Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4163-71 | 5.6 | 43 |
| 171 | The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. *Cell Cycle*, **2015**, 14, 1082-9 | 4.7 | 44 |
| 170 | 25-Hydroxyvitamin D Can Interfere With a Common Assay for 1,25-Dihydroxyvitamin D in Vitamin D Intoxication. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 2883-9 | 5.6 | 11 |
| 169 | Molecular and Clinical Aspects of Pseudohypoparathyroidism **2015**, 781-805 | | 1 |
| 168 | Primary Hyperparathyroidism in Children and Adolescents **2015**, 389-399 | | 2 |
| 167 | Exome sequencing reveals a nonsense mutation in MMP13 as a new cause of autosomal recessive metaphyseal anadysplasia. *European Journal of Human Genetics*, **2015**, 23, 264-6 | 5.3 | 12 |
| 166 | A comprehensive study of long-term skeletal changes after spinal cord injury in adult rats. *Bone Research*, **2015**, 3, 15028 | 13.3 | 20 |
| 165 | Teriparatide as a systemic treatment for lower extremity nonunion fractures: a case series. *Endocrine Practice*, **2015**, 21, 136-42 | 3.2 | 16 |
| 164 | CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1005-13 | 5.6 | 65 |
| 163 | Generation of mice encoding a conditional null allele of Gcm2. *Transgenic Research*, **2014**, 23, 631-41 | 3.3 | 8 |
| 162 | Mutations in the ABCC6 gene as a cause of generalized arterial calcification of infancy: genotypic overlap with pseudoxanthoma elasticum. *Journal of Investigative Dermatology*, **2014**, 134, 658-665 | 4.3 | 58 |
| 161 | National Health and Nutrition Examination Survey whole-body dual-energy X-ray absorptiometry reference data for GE Lunar systems. *Journal of Clinical Densitometry*, **2014**, 17, 344-77 | 3.5 | 68 |
| 160 | Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 2366-75 | 12.7 | 99 |
| 159 | Ketotic hypercalcemia: a case series and description of a novel entity. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1531-6 | 5.6 | 11 |
| 158 | Evaluating children with fractures for child physical abuse. *Pediatrics*, **2014**, 133, e477-89 | 7.4 | 185 |
| 157 | Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 7-11 | 5.6 | 57 |

| | | | |
|---|---|---|---|
| 156 | Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E1774-83 | 5.6 | 69 |
| 155 | A meta-analysis comparing the biochemistry of primary hyperparathyroidism in youths to the biochemistry of primary hyperparathyroidism in adults. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4555-64 | 5.6 | 26 |
| 154 | Receptor transduction pathways mediating hormone action **2014**, 34-89.e2 | | 4 |
| 153 | Vitamin D Metabolism or Action **2013**, 1-28 | | |
| 152 | Hypocalcemia in the critically ill patient. *Journal of Intensive Care Medicine*, **2013**, 28, 166-77 | 3.3 | 85 |
| 151 | Determination of reference intervals for serum total calcium in the vitamin D-replete pediatric population. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1946-50 | 5.6 | 11 |
| 150 | Hypoparathyroidism and Pseudohypoparathyroidism **2013**, 579-589 | | 5 |
| 149 | The role of SH3BP2 in the pathophysiology of cherubism. *Orphanet Journal of Rare Diseases*, **2012**, 7 Suppl 1, S5 | 4.2 | 63 |
| 148 | Cherubism: best clinical practice. *Orphanet Journal of Rare Diseases*, **2012**, 7 Suppl 1, S6 | 4.2 | 107 |
| 147 | Cloning and characterization of the human SH3BP2 promoter. *Biochemical and Biophysical Research Communications*, **2012**, 425, 25-32 | 3.4 | 4 |
| 146 | A multinational study to develop universal standardization of whole-body bone density and composition using GE Healthcare Lunar and Hologic DXA systems. *Journal of Bone and Mineral Research*, **2012**, 27, 2208-16 | 6.3 | 97 |
| 145 | Primary hyperparathyroidism in children and adolescents. *Journal of the Chinese Medical Association* , **2012**, 75, 425-34 | 2.8 | 68 |
| 144 | An update on the clinical and molecular characteristics of pseudohypoparathyroidism. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2012**, 19, 443-51 | 4 | 73 |
| 143 | A novel mutation in the GCM2 gene causing severe congenital isolated hypoparathyroidism. *Journal of Pediatric Endocrinology and Metabolism*, **2012**, 25, 741-6 | 1.6 | 14 |
| 142 | Mapping structural determinants within third intracellular loop that direct signaling specificity of type 1 corticotropin-releasing hormone receptor. *Journal of Biological Chemistry*, **2012**, 287, 8974-85 | 5.4 | 12 |
| 141 | Assessing bone health in children and adolescents. *Indian Journal of Endocrinology and Metabolism*, **2012**, 16, S205-12 | 1.7 | 28 |
| 140 | Acute diaphragmatic rupture in a patient with Ehlers-Danlos syndrome. *Journal of Emergency Medicine*, **2011**, 41, 366-8 | 1.5 | 10 |
| 139 | Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy. *PLoS ONE*, **2011**, 6, e21755 | 3.7 | 29 |

| | | | |
|---|---|---|---|
| 138 | Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. *Calcified Tissue International*, **2011**, 88, 370-7 | 3.9 | 10 |
| 137 | Decreased SH3BP2 inhibits osteoclast differentiation and function. *Journal of Orthopaedic Research* , **2011**, 29, 1521-7 | 3.8 | 4 |
| 136 | Madelung-like deformity in pseudohypoparathyroidism type 1b. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E1507-11 | 5.6 | 37 |
| 135 | Vitamin D status in abused and nonabused children younger than 2 years old with fractures. *Pediatrics*, **2011**, 127, 835-41 | 7.4 | 67 |
| 134 | Bone mineral density in pseudohypoparathyroidism type 1a. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4465-75 | 5.6 | 31 |
| 133 | Hypercalcemia in children and adolescents. *Current Opinion in Pediatrics*, **2010**, 22, 508-15 | 3.2 | 77 |
| 132 | Comparison of metabolism of vitamins D2 and D3 in children with nutritional rickets. *Journal of Bone and Mineral Research*, **2010**, 25, 1988-95 | 6.3 | 36 |
| 131 | SH3BP2 mutations potentiate osteoclastogenesis via PLC*Journal of Orthopaedic Research*, **2010**, 28, 1425-30 | 3.8 | 7 |
| 130 | A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4372-9 | 5.6 | 50 |
| 129 | Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/type IIc sodium-phosphate cotransporter: presentation as hypercalciuria and nephrolithiasis. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4433-8 | 5.6 | 47 |
| 128 | Imprinting status of Galpha(s), NESP55, and XLalphas in cell cultures derived from human embryonic germ cells: GNAS imprinting in human embryonic germ cells. *Clinical and Translational Science*, **2009**, 2, 355-60 | 4.9 | 9 |
| 127 | Pseudohypoparathyroidism type 1A and morbid obesity in infancy. *Endocrine Practice*, **2009**, 15, 249-53 | 3.2 | 20 |
| 126 | Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. *Cellular Signalling*, **2008**, 20, 40-9 | 4.9 | 20 |
| 125 | SH3BP2 is an activator of NFAT activity and osteoclastogenesis. *Biochemical and Biophysical Research Communications*, **2008**, 371, 644-8 | 3.4 | 32 |
| 124 | Preimplantation genetic diagnosis for severe albright hereditary osteodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 901-4 | 5.6 | 15 |
| 123 | Analysis of the GCM2 gene in isolated hypoparathyroidism: a molecular and biochemical study. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1426-32 | 5.6 | 38 |
| 122 | Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. *Molecular Endocrinology*, **2008**, 22, 2505-19 | | 25 |
| 121 | Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1073-9 | 5.6 | 155 |

| | | | |
|---|---|---|---|
| 120 | SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. *Clinical Orthopaedics and Related Research*, **2007**, 459, 22-7 | 2.2 | 15 |
| 119 | Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. *Critical Care Medicine*, **2007**, 35, 2071-5 | 1.4 | 92 |
| 118 | Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. *Human Mutation*, **2006**, 27, 717-8 | 4.7 | 40 |
| 117 | Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. *Molecular Endocrinology*, **2006**, 20, 3179-95 | | 44 |
| 116 | Differential responses of corticotropin-releasing hormone receptor type 1 variants to protein kinase C phosphorylation. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 1032-42 | 4.7 | 32 |
| 115 | Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl. *Clinical Chemistry*, **2006**, 52, 2286-93 | 5.5 | 14 |
| 114 | Weakness and mental status change. *Journal of Emergency Medicine*, **2006**, 30, 341-4 | 1.5 | 2 |
| 113 | Disorders of the Parathyroid Gland **2006**, 357-364 | | |
| 112 | Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. *Molecular Endocrinology*, **2005**, 19, 474-90 | | 64 |
| 111 | Chest pain and arthritis. *Journal of Emergency Medicine*, **2005**, 29, 91-5 | 1.5 | 2 |
| 110 | Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. *PLoS Genetics*, **2005**, 1, e82 | 6 | 175 |
| 109 | Reduction in Gsalpha induces osteogenic differentiation in human mesenchymal stem cells. *Clinical Orthopaedics and Related Research*, **2005**, 231-8 | 2.2 | 39 |
| 108 | A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. *Endocrinology*, **2005**, 146, 4697-709 | 4.8 | 112 |
| 107 | A highly sensitive polymerase chain reaction method detects activating mutations of the GNAS gene in peripheral blood cells in McCune-Albright syndrome or isolated fibrous dysplasia. *Journal of Bone and Joint Surgery - Series A*, **2005**, 87, 2489-94 | 5.6 | 33 |
| 106 | The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. *Chest*, **2005**, 128, 1951-7 | 5.3 | 20 |
| 105 | A HIGHLY SENSITIVE POLYMERASE CHAIN REACTION METHOD DETECTS ACTIVATING MUTATIONS OF THE GNAS GENE IN PERIPHERAL BLOOD CELLS IN MCCUNE-ALBRIGHT SYNDROME OR ISOLATED FIBROUS DYSPLASIA. *Journal of Bone and Joint Surgery - Series A*, **2005**, 87, 2489-2494 | 5.6 | 2 |
| 104 | Primary hyperparathyroidism: 7,000 years of progress. *Cleveland Clinic Journal of Medicine*, **2005**, 72, 1084-5, 1088, 1091-2 passim | 2.8 | 6 |
| 103 | Genetic Causes of Hypoparathyroidism **2005**, 159-178 | | 1 |

| | | | |
|---|---|---|---|
| 102 | Protein kinase A-induced negative regulation of the corticotropin-releasing hormone R1alpha receptor-extracellularly regulated kinase signal transduction pathway: the critical role of Ser301 for signaling switch and selectivity. *Molecular Endocrinology*, **2004**, 18, 624-39 | | 43 |
| 101 | Expression of GCMB by intrathymic parathyroid hormone-secreting adenomas indicates their parathyroid cell origin. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 8-12 | 5.6 | 29 |
| 100 | Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. *Journal of Biological Chemistry*, **2004**, 279, 22624-34 | 5.4 | 122 |
| 99 | Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7711-5 | 11.5 | 542 |
| 98 | Perinatal calcium metabolism: physiology and pathophysiology. *Seminars in Fetal and Neonatal Medicine*, **2004**, 9, 23-36 | | 78 |
| 97 | Normal mineral homeostasis. Interplay of parathyroid hormone and vitamin D. *Endocrine Development*, **2003**, 6, 14-33 | | 14 |
| 96 | Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4059-69 | 5.6 | 130 |
| 95 | Clinical management of primary hyperparathyroidism and thresholds for surgical referral: a national study examining concordance between practice patterns and consensus panel recommendations. *Endocrine Practice*, **2003**, 9, 494-503 | 3.2 | 20 |
| 94 | The pseudohypoparathyroidism type lb locus is linked to a region including GNAS1 at 20q13.3. *Journal of Bone and Mineral Research*, **2003**, 18, 424-33 | 6.3 | 16 |
| 93 | Genetic basis for resistance to parathyroid hormone. *Hormone Research in Paediatrics*, **2003**, 60 Suppl 3, 87-95 | 3.3 | 26 |
| 92 | Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?. *Journal of Pediatrics*, **2003**, 142, 532-8 | 3.6 | 39 |
| 91 | Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at GNAS1. *American Journal of Human Genetics*, **2003**, 73, 314-22 | 11 | 43 |
| 90 | A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. *European Journal of Endocrinology*, **2003**, 148, 25-30 | 6.5 | 41 |
| 89 | Biochemical markers of bone metabolism: application to understanding bone remodeling in children and adolescents. *Journal of Pediatric Endocrinology and Metabolism*, **2003**, 16 Suppl 3, 661-72 | 1.6 | 1 |
| 88 | Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. *Journal of Bone and Mineral Research*, **2002**, 17, 1102-10 | 6.3 | 171 |
| 87 | Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. *New England Journal of Medicine*, **2002**, 346, 99-106 | 59.2 | 248 |
| 86 | Decreased expression of the GHRH receptor gene due to a mutation in a Pit-1 binding site. *Molecular Endocrinology*, **2002**, 16, 450-8 | | 66 |
| 85 | Molecular pathogenesis of hypophosphatemic rickets. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 2467-73 | 5.6 | 64 |

| | | | |
|---|---|---|---|
| 84 | Asthma, allergy, and airway hyperresponsiveness are not linked to the beta(2)-adrenoceptor gene. *Chest*, **2002**, 121, 722-31 | 5.3 | 8 |
| 83 | Consensus development for the supplementation of vitamin D in childhood and adolescence. *Hormone Research in Paediatrics*, **2002**, 58, 39-51 | 3.3 | 50 |
| 82 | Localisation of mesenchymal tumours by somatostatin receptor imaging. *Lancet, The*, **2002**, 359, 761-3 | 40 | 172 |
| 81 | Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. *Biochemical and Biophysical Research Communications*, **2002**, 296, 67-72 | 3.4 | 126 |
| 80 | Genetic Control of Parathyroid Gland Development and Molecular Insights into Hypoparathyroidism **2002**, 181-192 | | |
| 79 | Pseudohypoparathyroidism **2002**, 1137-1163 | | 9 |
| 78 | Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children Center experience 1984-2001. *Journal of Bone and Mineral Research*, **2002**, 17 Suppl 2, N44-50 | 6.3 | 19 |
| 77 | Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. *Clinical Endocrinology*, **2001**, 54, 301-7 | 3.4 | 20 |
| 76 | Isolated growth hormone (GH) deficiency due to compound heterozygosity for two new mutations in the GH-releasing hormone receptor gene. *Clinical Endocrinology*, **2001**, 54, 681-7 | 3.4 | 38 |
| 75 | Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. *Journal of Neurochemistry*, **2001**, 76, 509-19 | 6 | 123 |
| 74 | Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s). A cause of pseudohypoparathyroidism type Ib. *Journal of Biological Chemistry*, **2001**, 276, 165-71 | 5.4 | 50 |
| 73 | Pseudohypoparathyroidism: Clinical, Biochemical, and Molecular Features **2001**, 807-825 | | 11 |
| 72 | Isolation and characterization of myostatin complementary deoxyribonucleic acid clones from two commercially important fish: Oreochromis mossambicus and Morone chrysops. *Endocrinology*, **2001** , 142, 1412-8 | 4.8 | 90 |
| 71 | Three new mutations in the gene for the growth hormone (gh)-releasing hormone receptor in familial isolated gh deficiency type ib. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 273-9 | 5.6 | 86 |
| 70 | FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. *Biochemical and Biophysical Research Communications*, **2001**, 284, 977-81 | 3.4 | 283 |
| 69 | ABSENT HEMATURIA AND EXPENSIVE COMPUTERIZED TOMOGRAPHY: CASE CHARACTERISTICS OF EMERGENCY UROLITHIASIS. *Journal of Urology*, **2001**, 165, 782-784 | 2.5 | 31 |
| 68 | The cAMP-protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. *Journal of Neuroscience*, **2001**, 21, 5297-303 | 6.6 | 125 |
| 67 | Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. *Journal of Clinical Investigation*, **2001**, 108, 1215-1220 | 15.9 | 149 |

| | | | |
|---|---|---|---|
| 66 | Signal Transduction of PTH and PTHrP **2001**, 117-126 | | |
| 65 | Guidelines for the Medical and Surgical Management of Primary Hyperparathyroidism **2001**, 451-457 | | |
| 64 | Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. *Journal of Bone and Mineral Research*, **2000**, 15, 2074-83 | 6.3 | 94 |
| 63 | Clinical spectrum and pathogenesis of pseudohypoparathyroidism. *Reviews in Endocrine and Metabolic Disorders*, **2000**, 1, 265-74 | 10.5 | 28 |
| 62 | Pseudohypoparathyroidism 1b: exclusion of parathyroid hormone and its receptors as candidate disease genes. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 2239-46 | 5.6 | 22 |
| 61 | Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. *Molecular Endocrinology*, **2000**, 14, 2076-91 | | 101 |
| 60 | Rapid parathyroid hormone measurement during venous localization. *Clinica Chimica Acta*, **2000**, 295, 193-8 | 6.2 | 16 |
| 59 | The Molecular Basis for Parathyroid Hormone Resistance in Pseudohypoparathyroidism **2000**, 179-209 | | |
| 58 | Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4118-26 | 5.6 | 70 |
| 57 | A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. *Molecular Endocrinology*, **1999**, 13, 2189-202 | | 100 |
| 56 | Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 917-23 | 5.6 | 171 |
| 55 | Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. *Endocrinology*, **1999**, 140, 1132-40 | 4.8 | 158 |
| 54 | Pseudohypoparathyroidism: from bedside to bench and back. *Journal of Bone and Mineral Research*, **1999**, 14, 1255-60 | 6.3 | 31 |
| 53 | Clinical implications of genetic defects in G proteins: oncogenic mutations in G alpha s as the molecular basis for the McCune-Albright syndrome. *Archives of Medical Research*, **1999**, 30, 522-31 | 6.6 | 56 |
| 52 | Pseudohypoparathyroidism **1999**, 39-58 | | |
| 51 | Coupling of the PTH/PTHrP receptor to multiple G-proteins. Direct demonstration of receptor activation of Gs, Gq/11, and Gi(1) by [alpha-32P]GTP-gamma-azidoanilide photoaffinity labeling. *Endocrine*, **1998**, 8, 201-9 | | 74 |
| 50 | Cost implications of different surgical management strategies for primary hyperparathyroidism. *Surgery*, **1998**, 124, 1028-35; discussion 1035-6 | 3.6 | 31 |
| 49 | Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 4435-42 | 5.6 | 83 |

| | | | |
|---|---|---|---|
| 48 | Reproductive dysfunction in women with Albright hereditary osteodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 824-9 | 5.6 | 52 |
| 47 | Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2658-65 | 5.6 | 147 |
| 46 | Hypoparathyroidism and Pseudohypoparathyroidism **1998**, 501-529 | | |
| 45 | Olfactory dysfunction in type I pseudohypoparathyroidism: dissociation from Gs alpha protein deficiency. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 247-50 | 5.6 | 21 |
| 44 | Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. *Endocrinology*, **1997**, 138, 3133-40 | 4.8 | 66 |
| 43 | Targeted disruption of Gnas in embryonic stem cells. *Endocrinology*, **1997**, 138, 4058-63 | 4.8 | 15 |
| 42 | Primary hyperparathyroidism. *Lancet, The*, **1997**, 349, 1233-8 | 40 | 100 |
| 41 | Normal parathyroid hormone responsiveness of bone-derived cells from a patient with pseudohypoparathyroidism. *Journal of Bone and Mineral Research*, **1996**, 11, 8-14 | 6.3 | 35 |
| 40 | Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. *Medicine (United States)*, **1996**, 75, 171-84 | 1.8 | 110 |
| 39 | [24] Molecular methods for analysis of genetic polymorphisms: Application to the molecular genetic study of genes encoding 2-adrenoceptor and stimulatory G protein subunit. *Methods in Neurosciences*, **1996**, 29, 379-400 | | |
| 38 | Probing the bimolecular interactions of parathyroid hormone and the human parathyroid hormone/parathyroid hormone-related protein receptor. 2. Cloning, characterization, and photoaffinity labeling of the recombinant human receptor. *Biochemistry*, **1995**, 34, 10553-9 | 3.2 | 48 |
| 37 | Reduced adenylyl cyclase activation with no decrease in beta-adrenergic receptors in basenji greyhound leukocytes: relevance to beta-adrenergic responses in airway smooth muscle. *Journal of Allergy and Clinical Immunology*, **1995**, 95, 860-7 | 11.5 | 11 |
| 36 | Albright hereditary osteodystrophy and del(2) (q37.3) in four unrelated individuals. *American Journal of Medical Genetics Part A*, **1995**, 58, 1-7 | | 91 |
| 35 | Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. *Journal of Bone and Mineral Research*, **1993**, 8, 83-91 | 6.3 | 71 |
| 34 | Stress alters adenylyl cyclase activity in the pituitary and frontal cortex of the rat. *Life Sciences*, **1993**, 53, 1719-27 | 6.8 | 14 |
| 33 | Impaired beta-adrenergic receptor activation of adenylyl cyclase in airway smooth muscle in the basenji-greyhound dog model of airway hyperresponsiveness. *American Journal of Respiratory Cell and Molecular Biology*, **1993**, 8, 668-75 | 5.7 | 37 |
| 32 | Enhanced expression of the inhibitory protein Gi2 alpha and decreased activity of adenylyl cyclase in lymphocytes of abstinent alcoholics. *Alcoholism: Clinical and Experimental Research*, **1993**, 17, 315-20 | 3.7 | 40 |
| 31 | A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of proopiomelanocortin secretion. *Endocrinology*, **1991**, 128, 1345-51 | 4.8 | 41 |

| | | | |
|---|---|---|---|
| 30 | Hormonal tolerance to ethanol is associated with decreased expression of the GTP-binding protein, Gs alpha, and adenylyl cyclase activity in ethanol-treated LS mice. *Alcoholism: Clinical and Experimental Research*, **1991**, 15, 705-10 | 3.7 | 52 |
| 29 | The McCune-Albright syndrome. The whys and wherefores of abnormal signal transduction. *New England Journal of Medicine*, **1991**, 325, 1738-40 | 59.2 | 26 |
| 28 | Mapping of the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase (GNAS1) to 20q13.2----q13.3 in human by in situ hybridization. *Genomics*, **1991**, 11, 478-9 | 4.3 | 86 |
| 27 | Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **1990**, 70, 1668-73 | 5.6 | 4 |
| 26 | Immunochemical analysis of the alpha-subunit of the stimulatory G-protein of adenylyl cyclase in patients with Albright hereditary osteodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **1990**, 71, 1208-14 | 5.6 | 49 |
| 25 | Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright hereditary osteodystrophy. *New England Journal of Medicine*, **1990**, 322, 1412-9 | 59.2 | 345 |
| 24 | Chromosomal localization of the genes encoding two forms of the G protein beta polypeptide, beta 1 and beta 3, in man. *Genomics*, **1990**, 8, 380-6 | 4.3 | 69 |
| 23 | Inhibition of glucose-stimulated insulin release in the perfused rat pancreas by parathyroid secretory protein-I (chromogranin-A). *Endocrinology*, **1989**, 124, 1235-8 | 4.8 | 45 |
| 22 | Familial Isolated Hypoparathyroidism. *Medicine (United States)*, **1986**, 65, 73-81 | 1.8 | 73 |
| 21 | Olfactory dysfunction in humans with deficient guanine nucleotide-binding protein. *Nature*, **1986**, 322, 635-6 | 50.4 | 67 |
| 20 | Membrane association of soluble protein activators of rat liver adenylate cyclase. Evidence for distinctness from the guanine nucleotide-binding stimulating protein (Ns). *Endocrine Research*, **1986**, 12, 269-91 | 1.9 | 1 |
| 19 | Evidence for normal antidiuretic responses to endogenous and exogenous arginine vasopressin in patients with guanine nucleotide-binding stimulatory protein-deficient pseudohypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **1986**, 62, 221-4 | 5.6 | 44 |
| 18 | Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine, and genetic analysis of Albright hereditary osteodystrophy in six kindreds. *Journal of Clinical Endocrinology and Metabolism*, **1986**, 62, 497-502 | 5.6 | 119 |
| 17 | The inhibitory adenylate cyclase coupling protein in pseudohypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **1985**, 61, 351-4 | 5.6 | 13 |
| 16 | Clinical implications of guanine nucleotide-binding proteins as receptor-effector couplers. *New England Journal of Medicine*, **1985**, 312, 26-33 | 59.2 | 121 |
| 15 | Infantile hypothyroidism in two sibs: an unusual presentation of pseudohypoparathyroidism type Ia. *Journal of Pediatrics*, **1985**, 107, 919-22 | 3.6 | 50 |
| 14 | Balanced rearrangement of chromosomes 2, 5, and 13 in a family with duplication 5q and fetal loss. *American Journal of Medical Genetics Part A*, **1984**, 19, 783-90 | | 15 |
| 13 | Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. *American Journal of Medicine*, **1983**, 74, 545-56 | 2.4 | 227 |

| | | | |
|---|---|---|---|
| 12 | Deficient guanine nucleotide regulatory unit activity in cultured fibroblast membranes from patients with pseudohypoparathyroidism type I. a cause of impaired synthesis of 3Q5Qcyclic AMP by intact and broken cells. *Journal of Clinical Investigation*, **1983**, 72, 316-24 | 15.9 | 64 |
| 11 | An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. *New England Journal of Medicine*, **1982**, 306, 257-64 | 59.2 | 148 |
| 10 | Familial hypocalciuric hypercalcemia: the relation to primary parathyroid hyperplasia. *New England Journal of Medicine*, **1982**, 307, 416-26 | 59.2 | 85 |
| 9 | The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. *Medicine (United States)*, **1981**, 60, 397-412 | 1.8 | 292 |
| 8 | Maximal urine-concentrating ability: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **1981**, 52, 736-40 | 5.6 | 104 |
| 7 | Intraoperative measurements of urinary cyclic AMP to guide surgery for primary hyperparathyroidism. *New England Journal of Medicine*, **1980**, 303, 1457-60 | 59.2 | 23 |
| 6 | Thyroid-Specific Expression of Cholera Toxin A1 Subunit Causes Thyroid Hyperplasia and Hyperthyroidism in Transgenic Mice | | 19 |
| 5 | Isolation and Characterization of Myostatin Complementary Deoxyribonucleic Acid Clones from Two Commercially Important Fish: Oreochromis mossambicusand Morone chrysops | | 33 |
| 4 | Thresholds for Surgery and Surgical Outcomes for Patients with Primary Hyperparathyroidism: A National Survey of Endocrine Surgeons | | 56 |
| 3 | Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site | | 22 |
| 2 | Chapter 75. Hypoparathyroidism and Pseudohypoparathyroidism354-361 | | 6 |
| 1 | McCuneAlbright Syndrome537-544 | | |